Adeno-Associated Viral Vector Delivered Cardiac-Specific and Hypoxia-Inducible VEGF Expression in the Ischemic Mouse Hearts
暂无分享,去创建一个
Y. Kan | W. Grossman | H. Su | S. Joho | J. Arakawa-Hoyt | A. Bárcena | Yu Huang
[1] S. Solomon,et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[2] M. Loda,et al. Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. , 2004, Biochemical and biophysical research communications.
[3] P. Krieg,et al. Molecular regulation of cardiac chamber-specific gene expression. , 2004, Trends in cardiovascular medicine.
[4] Y. Kan,et al. Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] T. Henry,et al. Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.
[6] K. Schmidt-Ott,et al. Vigilant Vector: Heart-Specific Promoter in an Adeno-Associated Virus Vector for Cardioprotection , 2002, Hypertension.
[7] E. Manseau,et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.
[8] Y. Kan,et al. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Pearlman,et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. , 2000, Journal of the American College of Cardiology.
[10] F. Agani,et al. Expression of hypoxia-inducible factor-1alpha in the brain of rats during chronic hypoxia. , 2000, Journal of applied physiology.
[11] H. Blau,et al. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.
[12] L. Kedes,et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. , 2000, Journal of the American College of Cardiology.
[13] Dian Feng,et al. Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.
[14] J. Isner,et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.
[15] J. Isner,et al. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. , 1998, Circulation.
[16] H. Blau,et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. , 1998, Molecular cell.
[17] P. Opolon,et al. Heart-specific targeting of beta-galactosidase by the ventricle-specific cardiac myosin light chain 2 promoter using adenovirus vectors. , 1998, Human gene therapy.
[18] L. Villarreal,et al. Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.
[19] B. V. von Specht,et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. , 1998, Circulation.
[20] H. Katus,et al. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters , 1997 .
[21] Takayuki Asahara,et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb , 1996, The Lancet.
[22] R. Harvey,et al. An HF-1a/HF-1b/MEF-2 combinatorial element confers cardiac ventricular specificity and established an anterior-posterior gradient of expression. , 1996, Development.
[23] Peipei Ping,et al. Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart , 1996, Nature Medicine.
[24] J. Pearlman,et al. Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis , 1995, Nature Medicine.
[25] J. Isner,et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. , 1994, Circulation.
[26] W Grossman,et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. , 1994, The Journal of clinical investigation.
[27] K. Chien,et al. Positive regulatory elements (HF-1a and HF-1b) and a novel negative regulatory element (HF-3) mediate ventricular muscle-specific expression of myosin light-chain 2-luciferase fusion genes in transgenic mice , 1994, Molecular and cellular biology.
[28] K. Chien,et al. Positional specification of ventricular myosin light chain 2 expression in the primitive murine heart tube. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[29] G. Brem,et al. Myosin light chain-2 luciferase transgenic mice reveal distinct regulatory programs for cardiac and skeletal muscle-specific expression of a single contractile protein gene. , 1992, The Journal of biological chemistry.
[30] K. Chien,et al. A conserved 28-base-pair element (HF-1) in the rat cardiac myosin light-chain-2 gene confers cardiac-specific and alpha-adrenergic-inducible expression in cultured neonatal rat myocardial cells , 1991, Molecular and cellular biology.
[31] B W Kimes,et al. Properties of a clonal muscle cell line from rat heart. , 1976, Experimental cell research.